Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction

American Heart Journal

Volumn 138, Issue 6 I, 1999, Pages 1158-1165

  Goldstein, S ^a   Kennedy, H L ^a   Hall, C ^a   Anderson, J L ^a   Gheorghiade, M ^a   Gottlieb, S ^a   Jessup, M ^a   Karlsberg, R P ^a   Friday, G ^a   Haskell, L ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METOPROLOL; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOLTER MONITORING; HUMAN; MALE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOISOTOPE VENTRICULOGRAPHY; RANDOMIZED CONTROLLED TRIAL;

EID: 0032757563     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70083-9     Document Type: Article

References (32)

1. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
2. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-14.
3. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-10.
4. Herlitz J, Hjalmarson A, Holmberg S, Swedberg K, Vedin A, Waagstein F, et al. Development of congestive heart failure after treatment with metoprolol in acute myocardial infarction. Br Heart J 1984;51:539-44.
5. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
6. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
7. The Metoprolol In Dilated Cardiomyopathy (MDC) Trial Study Group. 3-Year follow-up of patients randomized in the Metoprolol in Dilated Cardiomyopathy Trial. Lancet 1998;351:1180-1.
8. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, et al. Effect of metroprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-20.
9. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PF, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-46.
10. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
11. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
12. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
13. Australia/New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
14. Hjalmarsson A. The Metoprolol succinate Randomized Intervention Trial in Heart Failure (MERIT-HF): Presented at the 48th Annual Meeting of the American College of Cardiology, New Orleans, Louisiana, March 1999.
15. Sandberg A, Ragnarsson G, Jonsson UE, Sjogren J. Design of a new multiple-unit controlled-release formulation of metoprolol-metoprolol CR/XL. Eur J Clin Pharmacol 1988;33(suppl):S3-S7.
16. Abrahamsson B, Lucker P, Olofsson B, Regardh CG, Sandberg A, Wieselgren I, et al. The relation between metoprolol plasma concentration and β-i-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations. J Clin Pharmacol 1990;30:S46-S54.
17. Rector TS, Kubo SH, Cohn JN. Patients self-assessment of their congestive heart failure: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987;3:198-209.
18. Kennedy metoprolol CR/XL. Importance of the standard electrocardiogram in ambulatory (Holter) electrocardiography. Am Heart J 1992;123:1660-77.
19. Cooper DH, Kennedy HL, Lyyski DS, Sprague MK. Holter "triage" ambulatory ECG analysis: accuracy and time efficiency. J Electrocardiology 1996;29:33-8.
20. Kennedy HL, Smith SC, Sprague MK, Mizera J, Buckingham TA. Limitations of ambulatory ECG real time analysis for ventricular and supraventricular arrhythmia accuracy detected by clinical evaluation. Am J Noninvas Cardiol 1992;6:137-46.
21. Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentrations of the n-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 1988;66:605-10.
22. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Circulation 1989;80:551-63.
23. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
24. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
25. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al for the Bucindolol Investigators. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994; 89:1632-42.
26. Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol 1989;14:564-70.
27. Anderson JL, Roder HE, Green LS. Comparative effects of β-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983;51:1196-202.
28. Lichstein E, Morganroth J, Harrist R, Husle E. Effect of Propranolol on Ventricular Arrhythmia: The β-Blocker Heart Attack Trial and experience. Circulation 1983;67(suppl I):I-5-10.
29. Kennedy HL, Brooks MM, Barker AH, et al, for the CAST Investigators. β-Blocker Therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1994;74:674-80.
30. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al for the European Myocardial Infarct Amiodarone Trial Investigators. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74.
31. Mathisen P, Hall C, Simonsen S. A Comparative study of atrial peptides ANF(1-980) and ANF(99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest 1993;53:41-9.
32. Klinge R, Polis A, Dickstein K, Hall C. Effects of angiotensin II receptor blockage on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure. J Cardiac Failure 1997;3:75-81.